Investors & Media Overview


Data Provided by Refinitiv.
Minimum 15 minutes delayed.

Learn More

Press Releases

23-May-23

CalciMedica Expands Executive Team with New Appointments

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing
15-May-23

CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

LA JOLLA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today reported financial results for the first quarter ended
20-Mar-23

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results in acute pancreatitis for
View All News